Cerus Corporation logo CERS - Cerus Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $4.00 DETAILS
HIGH: $4.00
LOW: $4.00
MEDIAN: $4.00
CONSENSUS: $4.00
UPSIDE: 28.21%

Stock News

Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress. “We look forward to highlighting how blood centers around the world are l.

Jun 17, 2026 04:30 AM • businesswire.com
Cerus Corporation Closes New Debt Facility of Up to $110 Million

Cerus Corporation Closes New Debt Facility of Up to $110 Million

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan. The refinancing is expected to reduce annual cash interest expense by up to $3.5 million, reflecting lower borrowing costs and an approximately $30 million reduction in outstanding term loan balance. Initial proceeds from the loan, togethe.

Jun 08, 2026 04:30 AM • businesswire.com
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena

Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders. *** May 27, 2026 Fellow Shareholders, I am an individual shareholder in Cerus managing my own capital. In light of the Company's negative returns and failure to achieve profitability over the past.

May 27, 2026 07:35 AM • businesswire.com
Cerus Corporation Announces First Quarter 2026 Financial Results

Cerus Corporation Announces First Quarter 2026 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex,” said William “Obi” Greenman, Cerus' president and chief executive officer. “As a result, we are raising our product revenue guidance for th.

Apr 30, 2026 12:01 PM • businesswire.com
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boute.

Apr 27, 2026 04:00 AM • businesswire.com
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the.

Apr 16, 2026 12:01 PM • businesswire.com
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. “Following a thorough succession planning process, this transition represents a natural step as we prepare for the nex.

Mar 16, 2026 12:05 PM • businesswire.com
Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference

Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference

Cerus (NASDAQ: CERS) executives used a presentation and fireside chat at the TD Cowen Healthcare Conference to reiterate the company's focus on making its INTERCEPT Blood System a global standard of care for transfusion medicine, while outlining commercial priorities across U.S. platelets, international expansion, and the company's INTERCEPT Fibrinogen Complex (IFC) franchise. Chairman, President and CEO

Mar 08, 2026 10:34 PM • defenseworld.net
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Ceru.

Mar 02, 2026 11:01 AM • businesswire.com
Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safe.

Feb 20, 2026 03:30 AM • businesswire.com
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor.

Feb 17, 2026 11:01 AM • businesswire.com

Price Targets